Primaquine is the only antimalarial drug available to clinicians for the treatment of relapsing
forms of malaria. Primaquine development and usage dates back to the 1940s and has …

There is a pressing need for compounds with broad-spectrum activity against malaria
parasites at various life cycle stages to achieve malaria elimination. However, this goal …

Abstract Background Primaquine (PQ), an 8-aminoquinoline, is the only drug approved by
the United States Food and Drug Administration for radical cure and prevention of relapse in …

Background Primaquine is the only drug providing radical cure of Plasmodium vivax
malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6 …

Eliminating the Plasmodium vivax malaria parasite infection remains challenging. One of the
main problems is its capacity to form hypnozoites that potentially lead to recurrent infections …

Objectives Characterization of the pharmacokinetic properties of the enantiomers of
primaquine and carboxyprimaquine following administration of racemic primaquine given …

Background There has been some evidence to suggest that the addition of chloroquine (CQ)
or quinine (QN) to 8-aminoquinoline (8-AQ) treatment regimens may increase the …

Background The activity and haemolytic toxicity associated with primaquine has been linked
to its reactive metabolites. The reactive metabolites are thought to be primarily formed …

Background The enantiomers of the 8-aminoquinoline anti-malarial primaquine have
different pharmacological properties. Development of an analytical method for simultaneous …

Background The clinical utility of primaquine (PQ), used as a racemic mixture of two
enantiomers, is limited due to metabolism-linked hemolytic toxicity in individuals with genetic …